concept

SASP

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SASP: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

57Connections

30Hypotheses

13Analyses

25Outgoing

32Incoming

20Experiments

20Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	SASP
Key Genes/Proteins	CDKN2A, cxcl10, MTOR
Related Diseases	Alzheimer's Disease, Alzheimer'S Disease, Aβ-induced neurotoxicity, fibrosis, microglial senescence
Related Pathways	BDNF expression, MAPK
Linked Hypotheses	40 hypotheses

Wiki Pages (5)

Knowledge base pages for this entity

Canonical Page

Validated Hypothesis: TBK1 Loss Locks Microglia in an Aged/Senescent Transcriptional State, Fueling ALS-Associated SASP

hypothesis · 1348 words

→

Pathway Diagram

graph TD
    SASP["SASP"]
    SASP -->|"expressed in"| Senescent_Microglia["Senescent Microglia"]
    SASP -->|"contributes to"| Neuroinflammation["Neuroinflammation"]
    SASP -->|"mediates"| chronic_inflammation["chronic inflammation"]
    SASP -->|"promotes"| tissue_dysfunction["tissue dysfunction"]
    SASP -->|"contributes to"| Alzheimer_s_Disease["Alzheimer's Disease"]
    SASP -.biomarker for.-> Cellular_Senescence["Cellular Senescence"]
    NF__B["NF-kappaB"] -->|"activates"| SASP
    NFKB["NFKB"] -->|"regulates"| SASP
    senescence["senescence"] -->|"causes"| SASP
    senescent_cells["senescent cells"] -->|"develops"| SASP
    NFKB1["NFKB1"] -->|"promotes"| SASP
    Senescent_Microglia -->|"expressed in"| SASP
    senomorphics["senomorphics"] -->|"inhibits"| SASP

Outgoing (25)

Target	Relation	Type	Str
Senescent Microglia	associated_with	cell_type	0.95
Senescent Microglia	expressed_in	cell_type	0.95
neuroinflammation	causes	mechanism	0.90
Neuroinflammation	associated_with	process	0.90
neurotoxic inflammation	causes	mechanism	0.90
chronic inflammation	mediates	process	0.90
chronic inflammation	promotes	process	0.90
tissue dysfunction	promotes	process	0.90
neuroinflammation	promotes	process	0.90
Neuroinflammation	causes	process	0.90
Aβ-induced neurotoxicity	promotes	phenotype	0.90
tau-induced neurotoxicity	promotes	phenotype	0.90
Neurodegeneration	promotes	process	0.85
Cellular Senescence	biomarker_for	process	0.85
Alzheimer's Disease	contributes_to	disease	0.85
MICROGLIA	interacts_with	cell_type	0.85
Alzheimer'S Disease	contributes_to	disease	0.80
neuroinflammation	activates	pathway	0.80
SENESCENCE	associated_with	entity	0.80
neuroinflammation	induces	process	0.80
neurodegenerative pathology	causes	phenotype	0.70
neuroinflammation	associated_with	phenotype	0.70
fibrosis	activates	disease	0.70
BDNF expression	inhibits	mechanism	0.70
tissue repair	protective_against	mechanism	0.50

Incoming (32)

Source	Relation	Type	Str
senescent cells	develops	cell_type	0.95
senescence	causes	process	0.95
NF-κB	activates	protein	0.95
NFKB	regulates	entity	0.95
NFKB1	promotes	protein	0.95
Senescent Microglia	associated_with	cell_type	0.95
NFKB	activates	protein	0.95
senescent glial cells	mediates	cell_type	0.90
Senescent Microglia	expressed_in	cell_type	0.90
cxcl10	associated_with	protein	0.90
senomorphics	inhibits	drug	0.90
microglial senescence	causes	process	0.90
microglial senescence	activates	phenotype	0.90
SDA-2026-04-01-gap-013	investigates	analysis	0.90
TGM2	drives	gene	0.85
Cys-D	suppresses	drug	0.85
Tgm2	upregulates	gene	0.80
NF-ΚB	regulates	pathway	0.80
MICROGLIA	promotes	cell_type	0.80
NF-κB	promotes	pathway	0.80
senescent pericytes	associated_with	cell_type	0.70
CCF formation	precedes	process	0.70
CDKN2A	activates	gene	0.70
MTOR	regulates	gene	0.70
MTOR inhibitors	associated_with	drug	0.70
senescent cells	activates	cell_type	0.70
TFEB	inhibits	protein	0.70
TFEB	modulates	transcription_factor	0.70
senescent microglia	causes	cell_type	0.70
senescent microglia	activates	cell_type	0.70
MAPK	causes	pathway	0.64
NLRP3	co_associated_with	gene	0.30

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
TBK1 Loss Locks Microglia in an Aged/Senescent Transcription	0.878	als	What are the mechanisms by which microgl
Microglial Senescence Prevention via TREM2/SASP Axis	0.837	neurodegeneration	Does the cancer-cystatin-C-TREM2 pathway
SASP-Mediated Complement Cascade Amplification	0.822	neurodegeneration	Senolytic therapy for age-related neurod
Targeting SASP-Complement Amplification Through HIF-1α Downs	0.793	neurodegeneration	What molecular mechanism causes VCP muta
SASP-Driven Aquaporin-4 Dysregulation	0.782	neurodegeneration	Senolytic therapy for age-related neurod

SASP-Mediated Cholinergic Synapse Disruption	0.763	neurodegeneration	Senolytic therapy for age-related neurod
Complement-SASP Amplification Cascade as Mechanistic Link	0.741	neurodegeneration	Why have anti-Aβ clinical trials failed
SASP Secretome-based Molecular Distinction via CXCL1/CXCL2/M	0.720	neurodegeneration	How can senescent microglia be molecular
SASP-Secreted MMP-9 from Senescent Microglia Generates Patho	0.718	als	What are the mechanisms by which microgl
TNF-α/IL-1β-Cx43 Hemichannel Axis as Upstream Link Between S	0.663	cell-biology	What is the relative contribution of con
SASP Modulation Rather Than Cell Elimination	0.660	-	Senescent cell clearance as neurodegener
SUMO1-Mediated Synaptotagmin-1 SUMOylation at Lys124 Impairs	0.652	neurodegeneration	What are the specific PTM changes in syn
SASP-Driven Microglial Metabolic Reprogramming in Synaptic P	0.643	neurodegeneration	Senolytic therapy for age-related neurod
NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Compl	0.592	neurodegeneration	test
NLRP3 Inflammasome Blockade as Upstream Intervention to Prev	0.566	neurodegeneration	Why have numerous phase 3 clinical trial
Timed Senolytic Therapy Eliminates p16^Ink4a/p21^Cip1-Senesc	0.564	neuroinflammation	What molecular mechanisms drive the tran
H2: SASP Neutralization via JAK/STAT Inhibition Preserves As	0.550	neurodegeneration	Do APOE4-driven senescent astrocytes cau
Combined NAMPT-Alectinib Targeting of SASP-Complement Cascad	0.549	neuroinflammation	How does Alectinib, a kinase inhibitor,
NFκB/C1Q SASP Modulation for Synaptic Protection	0.534	neurodegeneration	What are the optimal oxygen pressure, du
SASP Transient Suppression vs. Senolytic Elimination: A Ther	0.520	neurodegeneration	-
SASP-Secreted MMP-9 from Senescent Microglia Disrupts TDP-43	0.511	als	What are the mechanisms by which microgl
Astrocyte senescence and SASP-driven neuroinflammation in AL	0.510	neurodegeneration	Test
TBK1 Loss Drives Microglial Senescence-SASP to Generate MMP-	0.499	als	What are the mechanisms by which microgl
TBK1 Deficiency Disrupts Microglial Metabolic Reprogramming,	0.390	als	What are the mechanisms by which microgl
NAD+-SIRT1-H3K9me3 restoration enables true senescence rever	0.380	alzheimers	Can metabolic interventions truly revers
TBK1 Loss Drives MMP-9-Mediated TDP-43 Fragmentation Through	0.376	als	What are the mechanisms by which microgl
P2RY12 activation induces cellular senescence in cerebral VS	0.373	neurodegeneration	How does P2RY12-mediated VSMC dysfunctio
SASP-Secreted MMP-9 from Senescent Microglia Disrupts Nuclea	0.361	als	What are the mechanisms by which microgl
TBK1 Loss Triggers Astrocyte-to-Neuron Senescence Propagatio	0.000	als	What are the mechanisms by which microgl
TBK1 Loss Triggers eIF2α-Mediated Translational Repression T	0.000	als	What are the mechanisms by which microgl

Mentioning Analyses (13)

Scientific analyses that reference this entity

What are the mechanisms by which microglial senescence contributes to ALS pathol

neurodegeneration | 2026-04-26 | 12 hypotheses Top: 0.878

Microglial senescence in Alzheimer and Parkinson disease progression

neurodegeneration | 2026-04-26 | 0 hypotheses

Does pericyte senescence drive BBB breakdown or result from neurodegeneration as

neurodegeneration | 2026-04-25 | 6 hypotheses Top: 0.720

How does pericyte senescence mechanistically promote glioma cell growth and inva

neurodegeneration | 2026-04-14 | 0 hypotheses

Why have numerous phase 3 clinical trials failed despite advances in understandi

neurodegeneration | 2026-04-12 | 1 hypotheses Top: 0.566

Experiments (20)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Single-cell RNA sequencing analysis of human atherosclerotic plaques	exploratory	Atherosclerosis	0.900	0.00	Human atherosclerotic plaque s	proposed	N/A
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co	clinical	Alzheimer's Disease	0.900	0.50	aortic endothelial cells	proposed	$6,550,000
Network pharmacology analysis of QTJD active compounds and pathways	exploratory	Mycoplasma pneumoniae pneumoni	0.900	0.00	computational network analysis	proposed	N/A
Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
Proposed experiment from debate on Synaptic pruning by microglia in ea	falsification	Alzheimer's Disease	0.400	0.50	mouse	proposed	$200,000
Proposed experiment from debate on Senolytics targeting p16/p21+ senes	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$80,000
Biomechanical Impact Profiles and Chronic Traumatic Encephalopathy Phe	clinical	Neurodegeneration	0.400	0.50	in_silico	proposed	$180,000
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$7,500,000
Experiment: Autoimmune Hypothesis Testing in AD	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxic	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
cGAS-STING Pathway Validation Study in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,100,000
Microglial Aging and Immune Memory in Neurodegeneration — Training the	validation	Alzheimer's Disease	0.400	0.50	human	proposed	$2,960,000
Microglial Contributions to Huntington's Disease Pathogenesis	validation	Neuroinflammation	0.400	0.50	human	proposed	$2,960,000
Mixed Pathology Effects on Parkinson's Disease Progression and Treatme	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
Proposed experiment from debate on Perivascular spaces and glymphatic	falsification	Neurodegeneration	0.400	0.50	mouse	proposed	$240,000
s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/	falsification	Neurodegeneration	0.400	0.50	mouse	proposed	$260,000
Proposed experiment from debate on Perivascular spaces and glymphatic	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$100,000
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
NPH Glymphatic System Interaction Experiment	clinical	Neurodegeneration	0.400	0.50	human	proposed	$5,460,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Aquaporin-4 in glymphatic system, and its implication for central nervous system [PMID:36796590]	Peng S, Liu J, Liang C, Yang L, Wang G	Neurobiol Dis	2023	2
Uncommon inflammatory/immune-related myelopathies. [PMID:34715593]	Valencia-Sanchez C, Flanagan EP	J Neuroimmunol	2021	2
Complement, Inflammasome, and Microglial Crosstalk in Glaucoma: From Neurodegene [PMID:41900887]	Chen TY, Wu N, Sun X	Life (Basel)	2026	1
Clinical, Immunological, and Vesicular Markers in Sarcopenia and Presarcopenia. [PMID:40917056]	Shuliko LM, Svarovsky DA, Spirina LV, Og	Front Biosci (Landmark Ed)	2025	1
CD47-blocking antibody interferes with neutrophil extracellular traps formation [PMID:39951937]	Diao Y, Hao M, Xie M, Hu X, Tan R, Wang	J Neuroimmunol	2025	1
Asparagine Endopeptidase Inhibition Attenuates Tissue Plasminogen Activator-Indu [PMID:40116141]	Xie G, Jiang G, Huang L, Sun S, Li X, Wu	CNS Neurosci Ther	2025	1
Systemic Neurodegeneration and Brain Aging: Multi-Omics Disintegration, Proteost [PMID:40868276]	Voicu V, Toader C, Șerban M, Covache-Bus	Biomedicines	2025	1
Complement C1q/C3-CR3 signaling pathway mediates abnormal microglial phagocytosi [PMID:38642614]	Han QQ, Shen SY, Liang LF, Chen XR, Yu J	Brain Behav Immun	2024	1
Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. [PMID:37384704]	Zhang T, Xu D, Trefts E, Lv M, Inuzuka H	Science	2023	1
Microglia regulation of synaptic plasticity and learning and memory. [PMID:34472455]	Cornell J, Salinas S, Huang HY, Zhou M	Neural Regen Res	2022	1
Glymphatic System Impairment in Alzheimer's Disease and Idiopathic Normal Pressu [PMID:31959516]	Reeves BC, Karimy JK, Kundishora AJ, Mes	Trends Mol Med	2020	1
Inebilizumab-cdon. [PMID:32936251]	Unknown	American journal of health-sys	2020	1
The glymphatic pathway in neurological disorders. [PMID:30353860]	Rasmussen MK, Mestre H, Nedergaard M	Lancet Neurol	2018	1
Complement and microglia mediate early synapse loss in Alzheimer mouse models. [PMID:27033548]	Hong S, Beja-Glasser VF, Nfonoyim BM, Fr	Science	2016	1
Panacis Quinquefolii Radix Polysaccharides Alleviate Depressive-Like Behaviors i [PMID:41914021]	Xie M, Feng L, Li R, Li M, Shen L, Zhang	CNS neuroscience & therapeutic	2026	0
Enhanced anticancer activity of nanoemulsified cardamom extract via modulation o [PMID:41658858]	["Soltani T", "Karimian M", "Vaziri H",	Biochemistry and biophysics re	2026	0
Vaccine-induced antibodies can limit Salmonella infection in the absence of comp [PMID:41738756]	Perez-Toledo M, Aksu-Istil K, Marcial-Ju	mBio	2026	0
β-Hydroxybutyrate improves glymphatic system function and alleviates cerebral ed [PMID:41535708]	Yu MJ, Xiong RQ, Wu JW, Li YC, Xie JX et	Acta Pharmacol Sin	2026	0
Neutrophil-microglia interaction drives motor dysfunction in a neuromyelitis opt [PMID:41665955]	Qi F, Lennon VA, Zhao S, Guo Y, Ding H e	J Clin Invest	2026	0
Safety and efficacy of ravulizumab in patients with NMOSD previously treated wit [PMID:41782198]	Bennett JL, Bhattacharyya S, Zabeti A, L	Mult Scler	2026	0

Debates (20)

Multi-agent debates referencing this entity

Extended debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Debate: TBK1 Loss Locks Microglia in an Aged/Senescent Transcriptional State, Fu

closed · Rounds: 4 · Score: 0.33 · 2026-04-27

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.44 · 2026-04-27

Hypothesis debate: SASP-Mediated Complement Cascade Amplification

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

Investigate how microglial senescence drives ALS progression through inflammatio

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: SASP Modulation Rather Than Cell Elimination

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

What are the mechanisms by which microglial senescence contributes to ALS pathol

closed · Rounds: 6 · Score: 0.75 · 2026-04-26

Microglial senescence in Alzheimer and Parkinson disease progression

closed · Rounds: 6 · Score: 0.50 · 2026-04-25

Related Research

Hypotheses and analyses mentioning SASP in their description or question text

SASP-Mediated Cholinergic Synapse Disruption

Score: 0.763 · neurodegeneration · 2026-04-02

## Mechanistic Overview SASP-Mediated Cholinergic Synapse Disruption starts from the claim that modulating MMP2/MMP9 wit

Complement-SASP Amplification Cascade as Mechanistic Link

Score: 0.741 · neurodegeneration · 2026-04-16

**Molecular Mechanism and Rationale** The complement-SASP amplification cascade represents a mechanistic nexus where ce

SASP Secretome-based Molecular Distinction via CXCL1/CXCL2/MMP-3 Ratio

Score: 0.720 · neurodegeneration · 2026-04-22

## Mechanistic Overview SASP Secretome-based Molecular Distinction via CXCL1/CXCL2/MMP-3 Ratio starts from the claim tha

SASP-Secreted MMP-9 from Senescent Microglia Generates Pathological TDP-43 C-Ter

Score: 0.718 · als · 2026-04-26

The hypothesis proposes that MMP-9 (matrix metalloproteinase-9), secreted via the senescence-associated secretory phenot

TNF-α/IL-1β-Cx43 Hemichannel Axis as Upstream Link Between SASP and Synaptic Pru

Score: 0.663 · cell-biology · 2026-04-13

## Mechanistic Overview TNF-α/IL-1β-Cx43 Hemichannel Axis as Upstream Link Between SASP and Synaptic Pruning starts from

SASP Modulation Rather Than Cell Elimination

Score: 0.660 · unknown disease · 2026-04-16

## Mechanistic Overview SASP Modulation Rather Than Cell Elimination starts from the claim that modulating NFKB1,IL1B,BD

SUMO1-Mediated Synaptotagmin-1 SUMOylation at Lys124 Impairs Calcium Sensing and

Score: 0.652 · neurodegeneration · 2026-04-16

## Mechanistic Overview SUMO1-Mediated Synaptotagmin-1 SUMOylation at Lys124 Impairs Calcium Sensing and Links Synaptic

SASP-Driven Microglial Metabolic Reprogramming in Synaptic Phagocytosis

Score: 0.643 · neurodegeneration · 2026-04-07

## Mechanistic Overview SASP-Driven Microglial Metabolic Reprogramming in Synaptic Phagocytosis starts from the claim th

NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification

Score: 0.592 · neurodegeneration · 2026-04-16

## Mechanistic Overview NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification starts from the

NLRP3 Inflammasome Blockade as Upstream Intervention to Prevent SASP Amplificati

Score: 0.566 · neurodegeneration · 2026-04-16

## Mechanistic Overview NLRP3 Inflammasome Blockade as Upstream Intervention to Prevent SASP Amplification starts from t

Timed Senolytic Therapy Eliminates p16^Ink4a/p21^Cip1-Senescent Microglia to Pre

Score: 0.564 · neuroinflammation · 2026-04-15

## Mechanistic Overview Timed Senolytic Therapy Eliminates p16^Ink4a/p21^Cip1-Senescent Microglia to Prevent SASP-Driven

H2: SASP Neutralization via JAK/STAT Inhibition Preserves Astrocyte Function

Score: 0.550 · neurodegeneration · 2026-04-22

## Mechanistic Overview H2: SASP Neutralization via JAK/STAT Inhibition Preserves Astrocyte Function starts from the cla

Combined NAMPT-Alectinib Targeting of SASP-Complement Cascade

Score: 0.549 · neuroinflammation · 2026-04-16

## Mechanistic Overview Combined NAMPT-Alectinib Targeting of SASP-Complement Cascade starts from the claim that modulat

NFκB/C1Q SASP Modulation for Synaptic Protection

Score: 0.534 · neurodegeneration · 2026-04-17

## Mechanistic Overview NFκB/C1Q SASP Modulation for Synaptic Protection starts from the claim that modulating not yet s

SASP

Understanding Entity Pages

Wiki Pages (5)

Cellular Senescence Therapeutic Targeting

Validated Hypothesis: SASP-Mediated Complement Cascade Amplification

Validated Hypothesis: Microglial Senescence Prevention via TREM2/SASP Axis

SASP (Senescence-Associated Secretory Phenotype) in Neurodegeneration

Validated Hypothesis: TBK1 Loss Locks Microglia in an Aged/Senescent Transcriptional State, Fueling ALS-Associated SASP

Pathway Diagram

Outgoing (25)

Incoming (32)

Targeting Hypotheses (30)

Mentioning Analyses (13)

What are the mechanisms by which microglial senescence contributes to ALS pathol

Microglial senescence in Alzheimer and Parkinson disease progression

Does pericyte senescence drive BBB breakdown or result from neurodegeneration as

How does pericyte senescence mechanistically promote glioma cell growth and inva

Why have numerous phase 3 clinical trials failed despite advances in understandi

Can P16INK4A expression reliably distinguish harmful from beneficial senescent m

What distinguishes truly senescent brain cells from merely dysfunctional reactiv

What is the optimal therapeutic window timing for autophagy enhancement versus s

How can senescent microglia be molecularly distinguished from beneficial activat

How do regional, age, and sex-dependent differences in microglial populations af

Senescent cell clearance as neurodegeneration therapy

Senescent cell clearance as neurodegeneration therapy

Senolytic therapy for age-related neurodegeneration

Experiments (20)

Related Papers (20)

Debates (20)

Extended debate: Metabolic Reprogramming to Reverse Senescence

Debate: TBK1 Loss Locks Microglia in an Aged/Senescent Transcriptional State, Fu

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: SASP-Mediated Complement Cascade Amplification

Investigate how microglial senescence drives ALS progression through inflammatio

Hypothesis debate: SASP Modulation Rather Than Cell Elimination

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

What are the mechanisms by which microglial senescence contributes to ALS pathol

Microglial senescence in Alzheimer and Parkinson disease progression

Related Research

SASP-Mediated Cholinergic Synapse Disruption

Complement-SASP Amplification Cascade as Mechanistic Link

SASP Secretome-based Molecular Distinction via CXCL1/CXCL2/MMP-3 Ratio

SASP-Secreted MMP-9 from Senescent Microglia Generates Pathological TDP-43 C-Ter

TNF-α/IL-1β-Cx43 Hemichannel Axis as Upstream Link Between SASP and Synaptic Pru

SASP Modulation Rather Than Cell Elimination

SUMO1-Mediated Synaptotagmin-1 SUMOylation at Lys124 Impairs Calcium Sensing and

SASP-Driven Microglial Metabolic Reprogramming in Synaptic Phagocytosis

NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification

NLRP3 Inflammasome Blockade as Upstream Intervention to Prevent SASP Amplificati

Timed Senolytic Therapy Eliminates p16^Ink4a/p21^Cip1-Senescent Microglia to Pre

H2: SASP Neutralization via JAK/STAT Inhibition Preserves Astrocyte Function

Combined NAMPT-Alectinib Targeting of SASP-Complement Cascade

NFκB/C1Q SASP Modulation for Synaptic Protection